Changes in Beneficial Ownership · 4
BridgeBio Pharma, Inc.
BBIONASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
wk-form4_1790029286.xml
Filing details
- Report period
- 2026-09-17
- Issuer
- BridgeBio Pharma, Inc.
- Issuer CIK
- 0001743881
- Trading symbol
- BBIO
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Kumar Neil
- Reporting owner CIK
- 0001742485
- Relationship
- Director · Officer
- Officer title
- Chief Executive Officer
- Address
- C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-17 | S · Form 4[F1] | 8,721 | D | 69.0136[F2] | 496,965 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.[F3] |
| Common Stock | 2026-09-17 | S · Form 4[F1] | 1,279 | D | 69.5696[F4] | 495,686 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.[F3] |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Disposed
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 3,568,447 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.[F3] |
| Common Stock | 750,000 | I | By NK 2026 GRAT[F5] |
| Common Stock | 243,327 | D |
Table key
- I
- Indirect
- D
- Direct
Footnotes
- F1
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.↩ 1↩ 2
- F2
- Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.↩ 1
- F3
- The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.↩ 1↩ 2↩ 3
- F4
- Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.↩ 1
- F5
- These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.↩ 1
Signature 1
- Signed
- /s/ Will Solis, Attorney-in-Fact
- Date
- 2026-09-21
Company context
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.